• Neuroendocrine gastroenteropancreatic tumors (GEP-NETs) constitute a heterogeneous group of tumors with location of the primary tumors in the gastric mucosa, pancreas, small and large intestine. • Epidemiologic data specific to site and type of GEP-NETs are scarce in the literature. • Evidence on the real-world value of new treatments largely relies on assessing burden of illness and estimating the size of the target population at the country or region level. • Due to the paucity of data on specific sub-groups of GEP-NETs, sizing the target population in order to support the real-world value of treatments represents a major challenge.
Two GEP-NET sub-populations were of interest:
Sub-population #1
Patients with stable/slow progressing well-differentiated functioning and non-functioning GEP-NETs and unresectable locally advanced/metastatic disease.
5-year population growth strategy
i. Crude prevalence and incidence rates for a broader GEP-NET population identified in the literature; ii.
Stratification of estimates according to the above subpopulations derived using proportions of GEP-NETs by site and type using clinical data and further stratification of epidemiologic data by clinical experts; iii.
Calculation of the target size for each subpopulation at baseline; iv.
Calculation of target population size growth over a 5-year horizon.
In the absence of published epidemiologic data on specific subpopulations, the population growth modeling strategy can be used to:  Estimate trends in target sub-populations corresponding to varying labeling hypotheses (such as the two presented here);  Highlight trends in the burden of disease in specific subpopulations;  Allow a better understanding of the population health impact of the disease.
Sub-population #2
Patients with stable/slow progressing well-differentiated, nonfunctioning GEP-NETs and unresectable locally advanced/metastatic disease. 
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